Merck & Co. snagged a potential drug in the burgeoning market for obesity medications in a deal worth as much as $2 billion.

MERCK snagged a potential drug in the burgeoning market for obesity medications in a deal worth as much as US$2 billion. Read ...

Merck & Co. Inc. has turned to Asia for a second time to get into the GLP-1 market, this time to Shanghai-based Hansoh ...

By licensing a drug from Hansoh, Merck signaled that it isn’t prepared to fully challenge its rivals' dominance in the GLP-1 ...

Merck threw its hat into the obesity race on Wednesday, inking a deal worth up to $2.01 billion with Hansoh Pharma for its ...

The Chinese Communist Party intends to add more nuclear arms to its growing arsenal while expanding its global influence and ...

Merck has entered a $2 billion licensing deal with China's Hansoh Pharma for an oral weight-loss drug, positioning itself ...

Merck announced a weight loss drug deal Wednesday with China-based Hansoh worth up to $2 billion for the pill code-named ...

News of Merck’s licensing of Hansoh’s preclinical medicine pressured shares in Viking and other obesity drug developers seen ...

Merck & Co. is doubling down on getting into the white-hot weight-loss drug market, scooping up a pill developed in China. Merck said Wednesday it will pay Hansoh Pharma $112 million upfront for the ...

The Fed is widely expected to reduce interest rates by 25 basis points at its meeting. With a rate cut broadly priced in, the ...

Merck partners with Hansoh Pharma for GLP-1 drug development, while analysts highlight Viking's obesity assets as key for ...